Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company’s web site at www.accentia.net.
- 17 years ago
QualityStocks
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Tags Rodman & Renshaw
Related Post
-
Strawberry Fields REIT Inc.’s (NYSE AMERICAN: STRW) CEO, Moishe Gubin, Reflects on the Company’s Milestones on Bell2Bell Podcast
Strawberry Fields REIT, Inc., is a self-administered real estate investment trust, focused on the acquisition…
-
SEGG Media Corporation (NASDAQ: SEGG) Undergoes Expansion, Experiences New Growth, and Unveils a New Website
SEGG Media has recently expanded its offering by launching SEGG Digital and SEGG Productions. The…
-
Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option…